InvestorsHub Logo
Followers 23
Posts 911
Boards Moderated 0
Alias Born 10/22/2015

Re: jimmy667 post# 86575

Wednesday, 01/04/2017 2:46:27 AM

Wednesday, January 04, 2017 2:46:27 AM

Post# of 465859
Personally, I'd think Biogen would love to partner with Anavex for the Ph 3 trial. Why? Assuming Aducanumab is approved, its side effects are considerable. 2-73 reduces brain inflammation and has been hypothesized as a good preventative of strokes. Those are the potential serious side effects of Aducanumab. The two could be given in combo and what is great is, unlike the 273-donepezil combo, the two drugs have different MOA's and do not compete with each other at receptor sites, nor hinder each others activity.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News